Neurocrine Biosciences (NBIX) Total Non-Current Liabilities (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Total Non-Current Liabilities for 17 consecutive years, with $1.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities rose 38.81% year-over-year to $1.4 billion; the trailing twelve-month figure through Jun 2026 stood at $1.4 billion (up 38.81% YoY), and the FY2025 full-year result was $1.2 billion, up 20.35% from the prior year.
• Total Non-Current Liabilities grew to $1.4 billion in Q2 2026 per NBIX's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.4 billion in Q2 2026 and bottomed at $554.3 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $863.8 million across 5 years, with a median of $845.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities decreased 14.49% in 2022, then jumped 56.57% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $631.2 million in 2022, then jumped by 44.66% to $913.1 million in 2023, then increased by 5.44% to $962.8 million in 2024, then grew by 20.35% to $1.2 billion in 2025, then gained by 18.05% to $1.4 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.4 billion, $1.2 billion, and $1.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.